Active — Not RecruitingPhase 1

Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants

Australia24 participantsStarted 2025-12-04

Plain-language summary

The purpose of this study is to determine the absolute bioavailability of SC administered cizutamig in healthy adult participants.

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. 18-65 years of age
✓. Body mass index 18-30 kg/m2 and weight 55-100 kg
✓. Individuals in good health
✓. Meets vaccination requirements as defined by the protocol
✓. Agree to abstain from consumption of alcohol within 48-hrs of study visits
✓. Agree to the use of highly effective contraception as defined by the protocol

✕. Active Infection
✕. Inadequate clinical laboratory parameters at Screening
✕. Receipt of or inability to discontinue any excluded therapies
✕. Individuals who will decline blood products
✕. Individuals with immediate household contacts with young children (eg, ≤ 6 years old) or immunocompromised persons
✕. History of drug or alcohol abuse within last 12 months
✕. Individuals who are hypersensitive to intravenous immunoglobulin (IVIg)
✕. History of severe allergic or anaphylactic reactions to mAb therapy (or recombination antibody-related fusion proteins) or any constituents of study drug

Absolute bioavailability

Timeframe: Baseline to 8 weeks

NCT IDNCT07236411

SponsorCandid Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-06